Literature DB >> 8812649

MCP-1: Structure/Activity Analysis

.   

Abstract

Structure/activity relationships underlying the function of monocyte chemoattractant protein-1 (MCP-1) have been probed by site-directed mutagenesis and indicate that the N-terminus of MCP-1 plays a critical role in activating the MCP-1 receptor, especially aspartate-3. However, a monocyte chemoattractant motif analogous to the ELR sequence of neutrophil-active chemokines has not yet been identified. Amino acids whose side chains project from one face of the first beta-pleated sheet of MCP-1 are also involved in biological activity as is arginine-24. Among C-C chemokines, position 24 is occupied by arginine only in MCP-1, -2, and -3, suggesting that arginine may be a substitution specific for monocyte chemoattractants. Several MCP-1 variants antagonize wild-type MCP-1 activity, the most potent being N-terminal deletion variants. One such variant lacking amino acids 2-8 (called 7ND) inhibits monocyte chemotaxis in response to wild-type MCP-1, but not in response to chemically crosslinked MCP-1 homodimers. This indicates that N-terminal deletion variants exert their effects as dominant negative inhibitors, which implies that MCP-1 activates its receptor as a dimer. This has profound biological implications and also suggests that the dimer interface may be a target for MCP-1 inhibitors. Finally, mutagenesis has demonstrated that murine MCP-1 consists of two domains. An N-terminal domain colinear with human MCP-1 contains all of murine MCP-1's chemoattractant activity. A C-terminal domain of 49 amino acids, which is rich in serine and threonine, contains an extensive amount of O-linked carbohydrate that accounts for 50% of murine MCP-1's apparent molecular size.

Entities:  

Year:  1996        PMID: 8812649     DOI: 10.1006/meth.1996.0083

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  9 in total

1.  Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor.

Authors:  B T Seet; R Singh; C Paavola; E K Lau; T M Handel; G McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

2.  The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency.

Authors:  Yao Yao; Stella E Tsirka
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

3.  Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting.

Authors:  T I Arefieva; T L Krasnikova; A V Potekhina; N U Ruleva; P I Nikitin; T I Ksenevich; B G Gorshkov; M V Sidorova; Zh D Bespalova; N B Kukhtina; S I Provatorov; E A Noeva; E I Chazov
Journal:  Inflamm Res       Date:  2011-07-10       Impact factor: 4.575

4.  Mouse monocyte chemoattractant protein 1 (MCP1) functions as a monomer.

Authors:  Yao Yao; Stella E Tsirka
Journal:  Int J Biochem Cell Biol       Date:  2014-08-12       Impact factor: 5.085

5.  Blocking of monocyte chemoattractant protein-1 during tubulointerstitial nephritis resulted in delayed neutrophil clearance.

Authors:  Ping Li; Gabriela E Garcia; Yiyang Xia; Wei Wu; Christine Gersch; Pyong Woo Park; Luan Truong; Curtis B Wilson; Richard Johnson; Lili Feng
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

6.  Proteolytic processing and inactivation of CCL2/MCP-1 by meprins.

Authors:  Christian Herzog; Randy S Haun; Sudhir V Shah; Gur P Kaushal
Journal:  Biochem Biophys Rep       Date:  2016-08-21

7.  Muscle-specific inflammation induced by MCP-1 overexpression does not affect whole-body insulin sensitivity in mice.

Authors:  Inkie J A Evers-van Gogh; Antwi-Boasiako Oteng; Sheril Alex; Nicole Hamers; Milene Catoire; Rinke Stienstra; Eric Kalkhoven; Sander Kersten
Journal:  Diabetologia       Date:  2015-12-12       Impact factor: 10.122

8.  Mutant monocyte chemoattractant protein-1 protein (7ND) inhibits osteoclast differentiation and reduces oral squamous carcinoma cell bone invasion.

Authors:  Shuyu Luo; Chuanxiang Zhou; Jianming Zhang; Mengshan Chen; Hongjie Li; Shanchuan Zheng; Jingjing Quan
Journal:  Oncol Lett       Date:  2018-03-21       Impact factor: 2.967

9.  7ND protein exerts inhibitory effects on both osteoclast differentiation in vitro and lipopolysaccharide‑induced bone erosion in vivo.

Authors:  Weilin Long; Jingjing Quan; Yiwen Liu; Jing Li; Qimei Gong; Hongwei Jiang
Journal:  Mol Med Rep       Date:  2020-05-05       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.